Enhancing enzyme production: Kemin invests in Chinese biotechnology firm

04 Mar 2019 --- US-based Kemin Industries has entered into a partnership with CRVAB Bio-technology Co., Ltd. based in Inner Mongolia, China, which seeks to enhance its ability for basic enzyme production and expansion in food applications. The investment will give Kemin fermentation and production capabilities and allow the company to directly control its production of enzymes.

“With this investment, we will be able to better serve more customers in the global feed enzymes markets and will become basic in enzyme production,” says Dr. Chris Nelson, President and CEO of Kemin Industries. “As a company founded on science and innovation to improve lives around the world, we are always searching for ways to create impact and this new partnership allows us to expand into areas like food and textile applications.”

Since 1980, Kemin has been involved in blending enzymes for feed but the new partnership will expand Kemin’s global reach, provide customers with higher quality solutions and greater consistency in enzyme products, notes the company. 

Kemin will have expanded resources for innovation, in both single and blended enzymes as well as probiotic product pipelines. Additionally, the company plans to work on a new product portfolio to bring enzyme products to market. 

The investment will also give Kemin one of the most efficient fermentation facilities in China. 

“This will significantly improve our capability and allow us to produce products meeting the highest international quality standards,” says Peijun Wu, Chairman of CRVAB Bio-technology Company, Ltd. 

“As the feed and animal production industry continues to evolve, customers are searching more aggressively for innovations that add real value,” adds GS Ramesh, Kemin Global Group President, Animal Nutrition and Health. “Kemin continues to be the key driver of product and technology innovations globally. This new partnership will further strengthen our capability to quickly scale up new innovations while maintaining our quality and safety standards for global regulatory requirements.”